Thursday, July 31, 2014

Top 5 Machinery Stocks To Watch For 2015

Top 5 Machinery Stocks To Watch For 2015: API Technologies Corp (ATNY)

API Technologies Corp. (API), incorporated on February 2, 1999, designs, develops and manufactures systems, subsystems, radio frequency (RF) and secure communications products, as well as provides electronics manufacturing and engineering services. Its product lines include engineered products (including unmanned aerial vehicles (UAVs), aiming systems and synthesizers), secure communications products (including TEMPEST and emanation security, encryption and secure networking products), subsystems and components (including custom hybrids, terminals, transistors and magnetics), RF and microwave products (including custom filters, amplifiers, connectors and antennas), sensors, and power systems. It operates in two segments: Systems & Subsystems, and Secure Systems & Information Assurance. In June 2013, API sold its Data Bus product line to Data Device Corporation.

The Company offers engineering services (including engineering and design for payloads, ground contr ol systems and commercial product design) and electronics manufacturing services (EMS), such as new product introductions (NPI) and prototypes, turnkey manufacturing and printed circuit board (PCB) assembly. It operates in North America, the United Kingdom, Mexico and China.

Systems & Subsystems

The Systems & Subsystems segment includes the products and services of its operating subsidiaries Spectrum, API Defense Inc., API Defense USA Inc., API Systems Inc., SenDEC, National Hybrid Group, API Electronics, Inc., TM Systems, Keytronics, Filtran Limited and Microwave Technology, Inc. (CMT). Its products and services include RF /microwave solutions, Engineered Systems and Products, Subsystems and Hybrids, Electronics Manufacturing Services, Power Solutions, Sensors and Measurement and Engineering Services. It specializes in the development of custom Integrated Microwave Assemblies (IMAs). It develops and markets engineered system! s and products, used fo r force protection, communication, surveillance and reconnai! ssance. Featured solutions include Unmanned Aerial Vehicles (UAVs) and systems, Unmanned Ground Vehicle (UGV) systems, aiming systems and synthesizers.

The Companys Custom designed and off-the-shelf subsystems from API support mission critical applications, such as communication equipment, aircraft subsystems systems, computer peripherals, process control equipment, and instrumentation. Featured products include custom hybrids, terminals, transistors and magnetics solutions. It deliver Electronics Manufacturing Services (EMS), including: New Product Introductions (NPI) and prototypes, turnkey manufacturing, Printed Circuit Board (PCB) assembly, electro-mechanical assembly, systems integration, test engineering, turnkey box build and supply chain services. Its power products offer commercial and defense customers superior power and energy efficiency. Products span power systems management, distribution, and panels, and custom-designed power supplies for de fense and aerospace applications.

The Company offers a range of precision sensors and control products, including position sensing solutions for precision guided munitions, gyros, accelerometers, and inertial measurement sensors for defense and aerospace applications, and position and temperature sensors for industrial and commercial applications. It offers a range of design and engineering services for both defense and commercial customers. Featured areas of expertise include payloads, ground control systems, RF, microwave and millimeterwave.

Secure Systems & Information Assurance

The Secure Systems & Information Assurance segment includes the products and services of its subsidiaries Cryptek, Emcon Emanation Control Inc., Secure Systems and Technologies and the Ion Networks division. API offers customers various secure network and hardware solutions, including Emanation Security, Tempest and secures network ac! cess, rug! gedized systems and secure networking products. Its products are marketed u! nder the ! Cryptek, ION, Emcon, SST and Netgard brand names. These product offerings are sold to governments and other international organizations that require the level of security in the areas of identity validation, network access management, TEMPEST network intrusion prevention, and secure and encrypted fax, computers and telephones.

The Companys products and services include Emanation Security and TEMPEST Products, Secure Networking Products, Encryption and Professional Services. The Companys emanation security products include computing systems, network and communications systems and office systems. Its security appliances and software intelligently enables secure information sharing and systems management across organizations and technologies. Service providers, IT and communications equipment manufacturers, enterprises and government agencies rely on its secure networking products for secure systems for remote management, database guards for secure informatio n sharing and secure virtual enclaves.

The Companys encryption products and services enable Federal, State and Local governments, Department of Defense agencies, the Department of Homeland Security and the Armed Services to interoperate securely across organizational boundaries and untrusted systems. Its professional services include information assurance and secure networking architecture and design solutions, emanation security testing and engineering and security certification and validation.

The Company competes with Aeroflex, Incorporated, Anaren Inc., Data Devices Inc., Kratos Defense & Security Solutions, Inc., DRS.Finmeccanica, Ducommun Incorporated, Cobham plc, Comtech EF Data Corp. and M/A-COM Technology Solutions Inc.

Advisors' Opinion:
  • [By Anna Prior]

    API Technologies Corp.(ATNY) said it has received a new order to supply high-power amplifier systems as part of a Defense Depar! tment mar! itime requirement. This initial order is part of a multimillion-dollar program with first production delivery set for May 2015, the company said. Shares jumped 6% to $2.81 premarket.

  • [By Laura Brodbeck]

    Thursday

    Earnings Expected From: Lindsay Corporation (NYSE: LNN), Emmis Communications Corporation (NASDAQ: EMMS), API Technologies Corp. (NASDAQ: ATNY) Economic Releases Expected: Australian unemployment rate, Japanese consumer confidence, French industrial output, Italian industrial output, Bank of England interest rate decision, US initial and continuing jobless claims

    Friday

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-machinery-stocks-to-watch-for-2015.html

Wednesday, July 30, 2014

Top 10 Medical Companies To Own In Right Now

By most measures, close to a third of Americans are overweight if the scientific BMI measurement is used. Some smaller portion are “morbidly obese”, at the far end of the yardstick of those who weight may cause severe health problems.

Most research by both academic institutions, and government bodies like the CDC, claim that the cost of obesity runs into the tens of billions of dollars a year, due to diabetes, heart disease, and the crippling impact on joints. Obesity’s medical side effects drive American healthcare costs higher, and there are no data which show the obesity problem improving.

New data from Gallup shows that many Americans who are obese are aware of the condition, but many fewer do anything meaningful to help themselves. More astonishingly, some people who are obese do not admit it.

Gallup reports:

Americans’ desire to lose weight does not necessarily translate into their doing anything to achieve it. While 51% of adults want to lose weight, barely half as many (25%) say they are seriously working toward that goal. This discrepancy between Americans’ weight-loss desires and behavior has existed for years.

Hot Trucking Stocks To Watch Right Now: Horizon Pharma Inc (HZNP)

Horizon Pharma, Inc. (Horizon), incorporated on March 23, 2010, is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Company�� other product, LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Company�� distribution partner, Mundipharma International Corporation Limited (Mundipharma). As of December 31, 2010, Horizon completed multiple Phase III clinical trials of LODOTRA. In addition to these product candidates, the Company has a pipeline of earlier-stage product candidates to treat pain-related diseases and chronic inflammation. On April 1, 2010, Horizon effected a recapitalization and acquisition pursuant to which Horizon Pharma, Inc. became a holding company, that operates through its wholly owned subsidiaries, Horizon Pharma USA, Inc. (formerly Horizon Therapeutics, Inc.) and Horizon Pharma AG (formerly Nitec Pharma AG (Nitec)).

DUEXIS

DUEXIS is a combination of 800 milligram ibuprofen and 26.6 milligram famotidine in a single pill and is indicated for the relief of signs and symptoms of rheumatoid arthritis (RA), and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal (GI), ulcers in patients who are taking ibuprofen for those indications. The Company has completed two Phase III clinical trials in a total of over 1,500 patients with mild to moderate pain or arthritis that demonstrated a significant reduction in the incidence of non-steroidal anti-inflammatory drugs (NSAID)-induced upper GI ulcers when treated with DUEXIS versus ibuprofen alone.

LODOTRA

LODOTRA is a programmed release formulation of low-dose prednisone, a well-established drug use! d to inhibit the production of various pro-inflammatory cytokines, which are proteins associated with joint inflammation in RA. LODOTRA has received regulatory approval in Europe for the treatment of moderate to severe, active RA in adults when accompanied by morning stiffness. As of December 31, 2010, the Company had completed two pivotal Phase III clinical trials of LODOTRA in a total of over 600 patients with RA. The first pivotal Phase III trial supported the approval of LODOTRA in Europe in March 2009, where it is approved for marketing in 14 European countries. LODOTRA achieved significant results and met the primary endpoint in each of the two pivotal Phase III clinical trials. Its LODOTRA product was developed and is owned by Horizon Pharma AG. As of December 31, 2010, the Company markets LODOTRA in Europe through three separate agreements. Pursuant to two separate agreements, it granted Merck Serono GmbH and Merck GesmbH, an affiliate of Merck Serono, the rights to distribute and market LODOTRA in each of Germany and Austria, respectively, and pursuant to the third agreement, it granted Mundipharma rights to distribute and market LODOTRA in the rest of Europe. The Company also has a manufacturing and supply agreement with Jagotec AG under which Jagotec or its affiliates manufacture and supply LODOTRA to the Company as bulk tablets.

The Company competes with Pfizer Inc., Pozen Inc., Abbott Laboratories and Amgen Inc.

Advisors' Opinion:
  • [By Lisa Levin]

    Horizon Pharma (NASDAQ: HZNP) shares reached a new 52-week high of $17.12 after the company announced its plans to acquire privately held Vidara Therapeutics International for around $660 million.

  • [By Bryan Murphy]

    After a 16% rally on Tuesday, it would be understandable is a newcomer wanted to steer clear of Horizon Pharma Inc. (NASDAQ:HZNP). After all, how much more upside can there be for this fairly typical small cap biotech stock. Yet, HZNP may well be one of the rare exceptions to the "tough to follow-through" tendency.

    For those not familiar, HZNP is a biopharma name with a couple of rheumatoid arthritis, COPD, and asthma drugs on the market... Duexis, and Rayos. There's a third drug in the pipeline - Lodotra, for polymyalgia rheumatica, though it's already approved as a treatment for RA.� Either way, Horizon Pharma Inc. is unique in the sense that though it's a small biopharma company, it's at least driving revenue with a handful of marketable products.

    The pipeline and portfolio are secondary at this point, however. What matters most to traders now is whether or not there's actually any upside left to tap into with Horizon Pharma. The answer is, it depends.

    Given just the nearby daily chart, no, it looks like HZNP has burned up all of its fuel. Aside from the fact that it's overextended now, Tuesday's volume spike also implies anybody who was thinking about buying went ahead and took the plunge. That may well mean nobody is left to keep buying tomorrow. There may well be, however, plenty of nervous-Nellie profit-takers ready to head for the exit.

    The assessment changes quite a bit when you zoom out to a longer-term chart of Horizon Pharma, though.

    While this won't allow the stock to sidestep a near-term pullback, Tuesday's pop was something a game-changer for the long-term chart. The move shook the stock out of a narrow range that had trapped the stock between $2.80 and $2.12 for the last ten months.



    The proverbial "so what" is, with nearly a years' worth of pent-up energy finally being unleashed, we're nowhere near the end of the final resting place. Once we burn off this initial, knee-jerk reaction to the

  • [By Jake L'Ecuyer]

    Leading and Lagging Sectors
    Wednesday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Horizon Pharma (NASDAQ: HZNP) and Pernix Therapeutics Holdings (NASDAQ: PTX). In trading on Wednesday, telecommunications services shares were relative laggards, down on the day by about 0.39 percent. Top decliners in the sector included Shenandoah Telecommunications Co (NASDAQ: SHEN), off 3.3 percent, and CalAmp (NASDAQ: CAMP), down around 2.4 percent.

Top 10 Medical Companies To Own In Right Now: Sirona Dental Systems Inc (SIRO)

Sirona Dental Systems, Inc. (Sirona), incorporated on April 25, 1997, and its subsidiaries is a manufacturer of dental equipment, and is focused on developing, manufacturing and marketing solutions for dentists around the world. The Company operates in four segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers and Instruments. The Company markets its products globally to dental practices, clinics and laboratories through an international network of distributors. The dental distributors supply both dental equipment and consumables, and have regular contact with the ultimate end-users. In addition, the Company also distributes its products through its own sales and services infrastructure.

Dental CAD / CAM Systems

Dental CAD/CAM Systems address the dental restorations, which includes several types of restorations, such as inlays, onlays, veneers, crowns, bridges, copings and bridge frameworks made from ceramic, metal or composite blocks. Sirona's CEramic REConstruction (CEREC) system is an in-office application that enables dentists to produce high quality restorations from ceramic material and insert them into the patient's mouth during a single appointment. The CEREC system consists of an imaging unit and a milling unit. The imaging unit scans the damaged area, captures the image of the tooth or teeth requiring restoration and proposes the specifications for the restoration. The milling unit then mills the ceramic restoration to the required specifications based upon the captured image and the dentist's design specifications.

Sirona offers a service contract on its CEREC product, which includes software updates and upgrades and maintenance on software-related hardware. In addition to CEREC, Sirona also offers CAD/CAM products for dental laboratories, including the inLab restoration fabrication system and the extra-oral inEos scanner. These products are designed to improve efficiency and reduce costs for the dental lab. The inLab system scans the ! models received from the dentists and then mills ceramic or composite block restorations, such as crown copings and bridge frameworks to the specifications of the captured image.

Imaging Systems

Imaging Systems comprise a broad range of systems for diagnostic imaging in the dental practice. Sirona has developed a comprehensive range of imaging systems for two dimensional (2D) or three dimensional (3D), panoramic and intra-oral applications. Intra-oral x-ray systems use image-capture sensor devices, which are inserted into the mouth behind the diagnostic area, and take images of one or two teeth. Panoramic x-ray systems produce images of the entire jaw structure by means of an x-ray tube and an image capture device, which rotates around the head.

Treatment Centers

Treatment Centers consists of a range of products from basic dentist chairs to chair-based units with integrated diagnostic, hygiene and ergonomic functionalities, as well as specialist centers used in preventative treatment and for training purposes. Sirona offers specifically configured products to meet the preferences of dentists within each region in which it operates. Sirona's treatment center configurations and system integration are designed to enhance productivity by creating a seamless workflow within the dental practice.

Instruments

Sirona offers a range of instruments, including handheld and power-operated handpieces for cavity preparation, endodontics, periodontology and prophylaxis, which are regularly updated and improved. The instruments are supplemented by multi-function tips, supply and suction hoses, as well as care and hygiene systems for instrument preparation. Sirona's instruments are often sold as packages in combination with treatment centers.

Advisors' Opinion:
  • [By John Udovich]

    Yesterday, small cap dental stock BIOLASE Inc (NASDAQ: BIOL) surged 17.69% after announcing it had received a license from the Health Canada-Medical Device Bureau to sell its EPIC dental soft-tissue diode laser systems throughout Canada, meaning its worth taking a closer look at the stock along with the performance of mid cap dental stocks like Sirona Dental Systems, Inc (NASDAQ: SIRO), DENTSPLY International Inc (NASDAQ: XRAY) and Align Technology, Inc (NASDAQ: ALGN).

  • [By Todd Campbell]

    Dentists may find that patients are more willing to spend on restorative procedures now that the job market is recovering and consumer sentiment is heading higher. That offers new opportunities for providers of dentistry equipment, such as Sirona Dental Systems (NASDAQ: SIRO  ) , a company that was spun out of Siemens in 1997 and brought public in 2006.

Top 10 Medical Companies To Own In Right Now: HeartWare International Inc (HTWR)

Heartware International, Inc. (HeartWare), incorporated on June 25, 2010, develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure. The HeartWare Ventricular Assist System (the HeartWare System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HeartWare System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HeartWare System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices. In August 2012, it acquired World Heart Corporation. As of December 31, 2012, the HeartWare System has been implanted outside of the United States at approximately 168 health care sites in 28 countries. In December 2013, HeartWare International Inc acquired CircuLite, Inc.

Proprietary Pump Technology

The HeartWare System is full-output centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. At the core of the Company�� technology platform is its hybrid system for suspending the impeller, which is the only moving part within the pump. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of

blood. Once power is applied to the device and the impeller begins to rotate, there are no points of mechanical contact within the pump, thus providing a completely wearless pumping system.

The HeartWare System

The HeartWare System consists of the HVAD Pump, a small, permanently implantable VAD, patient accessories and surgical tools. The HVAD Pump is capable of generating up to 10 liters of blood flow per minute. With a displaced v! olume of only 50 cubic centimeters and a mass of 140 grams, the HVAD Pump is the only full-output pump implantable in the pericardial space, directly adjacent to the heart. It is also the only pump designed to be implanted above the diaphragm in all eligible patients.

The HeartWare MVAD

The miniaturized ventricular assist device (MVAD) is a miniaturized blood pump intended for chronic heart failure patients. The device is a full-output axial flow pump with a fully suspended rotor and a displacement volume approximately one-third that of the HVAD Pump.

The Company competes with Thoratec Corporation, Jarvik Heart, MicroMed Technology, Inc, Berlin Heart AG, Terumo Heart, Inc., Sunshine Heart, Inc and CircuLite, Inc., Evaheart Medical USA, Inc.

Advisors' Opinion:
  • [By Lauren Pollock]

    Medical device company HeartWare International Inc.(HTWR) issued a revenue forecast that fell short of market expectations.

    Intrepid Potash Inc.(IPI), the largest potash producer in the U.S., plans to cut its workforce by 7% and cut executive compensation as part of a plan to trim costs in reaction to weaker prices for the fertilizer ingredient.

  • [By Todd Campbell]

    Competing for heart pump market share
    Abiomed's products provide circulatory support for up to six hours and are designed for use in cardiac cath labs or during heart surgery, but competitors Thoratec (NASDAQ: THOR  ) and Heartware (NASDAQ: HTWR  ) target the intermediate- and long-term-use market instead.

Top 10 Medical Companies To Own In Right Now: Boston Therapeutics Inc (BTHE)

Boston Therapeutics, Inc. is a development-stage company. The Company�� business is the development, manufacture and commercialization of therapeutic drugs and dietary supplements with a focus on glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company is focusing on three products: IPOXYN, an injectable anti-hypoxia drug, which it is developing; PAZ320, which is a non-systemic, chewable drug candidate for reduction of blood glucose in diabetics in development and SUGARDOWN, a complex carbohydrate-based chewable dietary supplement, which it is marketing. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the class of carbohydrate-hydrolyzing enzyme inhibitors.

SUGARDOWN

The Company has developed SUGARDOWN, a non-systemic complex carbohydrate-based dietary supplement to moderate post-meal blood glucose using processes and technology. It has unrestricted access to both sufficient raw materials at commodity pricing and processing facilities to produce sufficient supply of SUGARDOWN to support product distribution across multiple sales channels as a dietary supplement. Its SUGARDOWN dietary supplement consists of a stabilized complex carbohydrate composition. The Company has completed development of SUGARDOWN as a dietary supplement. On January 24, 2012 the Company announced the clinical trial results in healthy volunteers performed at the University of Sydney on SUGARDOWN.

PAZ320

PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes, which release glucose from complex carbohydrate in foods during digestion, reducing the amount of available glucose absorbed through the intestine. PAZ320 is in development as a drug candidate. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the! class of carbohydrate-hydrolyzing enzyme inhibitors.

IPOXYN

The Company has developed a drug candidate product IPOXYN, a glyco-protein based therapeutic agent. Its IPOXYN anti-hypoxia drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support. In addition to potential uses for human patients, it also focuses to file a registration for IPOXYN for veterinary applications under the name OXYFEX. The Company�� pharmaceutical agents are intended for intravenous administration into the circulatory system to target acute and late stage diseases.

Advisors' Opinion:
  • [By CRWE]

    Today, BTHE remains (0.00%) +0.000 at $1.10 thus far (ref. google finance Delayed: 12:25PM EDT October 10, 2013).

    Boston Therapeutics has previously closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors (the “Offering”).
    Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes. PAZ320 is the first compound in a new class of therapies for this disease.

Top 10 Medical Companies To Own In Right Now: DENTSPLY International Inc.(XRAY)

DENTSPLY International Inc. designs, develops, manufactures, and markets dental consumable products, dental laboratory products, and dental specialty products worldwide. The company?s dental consumable products include dental sundries, such as dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride; and small equipment, including high and low speed handpieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers used in dental offices for the treatment of patients. Its dental laboratory products comprise dental prosthetics, including artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials, as well as equipment, such as computer aided machining ceramic systems and porcelain furnaces used in the preparation of dental appliances by dental laboratories. The company?s dental specialty products consist of endodonti c instruments and materials, implants and related products, bone grafting materials, 3D digital implantology, and orthodontic appliances and accessories. Its customers include dentists, dental hygienists, dental assistants, dental laboratories, and dental schools. The company distributes its dental products directly to dental laboratories and dental professionals, as well as through distributors, dealers, and importers. DENTSPLY International Inc. was founded in 1983 and is headquartered in York, Pennsylvania.

Advisors' Opinion:
  • [By Ben Levisohn]

    Shares of Align have surged 24% to $57 at 12:37 p.m. Sirona Dental Systems (SIRO) has risen 0.8% to $69.61, Dentsply International (XRAY) is up 0.1% at $45.44, Integra Lifesciences (IART) has� gained 0.4% to $44.23 and Danaher (DHR) has fallen 0.3% to $72.13.

  • [By John Udovich]

    Yesterday, small cap dental stock BIOLASE Inc (NASDAQ: BIOL) surged 17.69% after announcing it had received a license from the Health Canada-Medical Device Bureau to sell its EPIC dental soft-tissue diode laser systems throughout Canada, meaning its worth taking a closer look at the stock along with the performance of mid cap dental stocks like Sirona Dental Systems, Inc (NASDAQ: SIRO), DENTSPLY International Inc (NASDAQ: XRAY) and Align Technology, Inc (NASDAQ: ALGN).

  • [By Monica Gerson]

    DENTSPLY International (NASDAQ: XRAY) shares touched a new 52-week high of $47.65. DENTSPLY's trailing-twelve-month ROE is 15.95%.

    Sun Life Financial (NYSE: SLF) shares gained 2.47% to create a new 52-week high of $34.80 on Q3 results. Sun Life reported its Q3 operating net income from continuing operations of $422 million.

Top 10 Medical Companies To Own In Right Now: Curis Inc.(CRIS)

Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, under collaboration with Genentech, Inc., is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase, epidermal growth factor receptor, and epidermal growth factor receptor 2. In addition, Curis has a development candidate, Debio 0932, which is a Heat Shock Protein 90 or Hsp90 inhibitor. The company holds a license agreement with Debiopharm related to its Hsp90 technologies. Further, it involves in preclinical testing for the development of candidates from its targeted cancer programs. The company was founded in 2000 and is base d in Lexington, Massachusetts.

Advisors' Opinion:
  • [By Monica Gerson]

    Curis (NASDAQ: CRIS) dipped 18.97% to $3.16 in the pre-market session after the company reported Q3 financial results and provided CUDC-427 development update.

Top 10 Medical Companies To Own In Right Now: Imprimis Pharmaceuticals Inc (IMMY)

Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company�� Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company�� lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.

Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it exerts its localized anti-inflammatory and analgesic effect. Transdel is the Company�� transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.

Advisors' Opinion:
  • [By John Udovich]

    So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

  • [By John Udovich]

    The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

Tuesday, July 29, 2014

Top Integrated Utility Stocks To Invest In Right Now

People know they aren't saving enough for their golden years, but at least they are talking about retirement with their significant other.

Couples say they discuss retirement planning an average of 14 times a year, according to a telephone survey of 1,008 adults sponsored by Capital One ShareBuilder, an online investing site.

The survey shows 72% of employed adults say they're contributing a percentage of their annual income to retirement, tucking away an average of 6.4% of their annual incomes. Overall, folks believe they should be saving about 12.1%.

If you are saving less than 10% for retirement, especially if you're in your 40s and 50s, that's not enough, says Dan Greenshields, president of Capital One ShareBuilder. Ideally, at that age, you should be saving in the mid-teens to 20% of your income, but most Americans can't save that much because they have so many financial demands, he says.

Top Integrated Utility Stocks To Invest In Right Now: SPDR DB International Government Inflation-Protected Bond ETF (WIP)

SPDR DB International Government Inflation-Protected Bond ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the DB Global Government ex-US Inflation-Linked Bond Capped Index (the Index). The Index measures the performance of the inflation-linked government bond markets of developed and emerging market countries outside of the United States. Inflation protected public obligations of the inflation-linked government bond markets of developed and emerging market countries, commonly known in the United States as treasury inflation-protected securities (TIPS), are securities issued by such governments that are designed to provide inflation protection to investors. The Fund uses a passive management strategy to track the Index. The Fund�� investment advisor is SSgA Funds Management, Inc. Advisors' Opinion:
  • [By Richard Stavros]

    With respect to inflation protected bonds, though TIPS should be a part of every portfolio. However, we believe the SPDR DB International Government Inflation-Protected Bond (WIP) offers greater protection than TIPS.

Top Integrated Utility Stocks To Invest In Right Now: Ausdrill Ltd (ASL)

Ausdrill Limited is a mining and energy services company providing exploration, mine development, surfacing and underground mining, manufacturing, energy and infrastructure services globally. The Company operates in five segments: Mining Services Australia, which includes the provision of mining services, including drilling and blasting, in-pit grade control, exploration drilling, earthmoving, waterwell drilling, energy drilling, equipment hire, equipment parts and sales and mineral analysis in Australia; Contract Mining Services Africa, which includes the provision of mining services, including drilling and blasting, in pit grade control, exploration drilling and earthmoving in Africa; Manufacturing, which includes manufacture of drilling rods and consumables, drill rigs and dump truck tray bodies; Supply and Logistics, which includes the provision of mining supplies and logistics services and Other, which includes its central functions like treasury, financing and administration. Advisors' Opinion:
  • [By Adam Haigh]

    Toyota Motor Corp. (7203), the world�� biggest carmaker, lost 1.3 percent in Tokyo after its net-income forecast fell short of analyst estimates. Ausdrill Ltd. (ASL) slumped 29 percent in Sydney after the drilling contractor said its expects a lower profit. GungHo Online Entertainment Inc. gained 2.5 percent as Japan Exchange Group Inc. and Nikkei Inc. said the Internet-game maker will be included in their new index.

Top 5 Media Companies For 2015: Ashmore Group PLC (ASHM)

Ashmore Group plc (Ashmore) is engaged in providing investment management services. The Company is a fund manager across six core investment themes, such as external debt, local currency, corporate debt, blended debt, equities, multi-strategy, alternatives and overlay/liquidity. External debt is a diversified portfolio of emerging market debt assets. Local currency takes advantage of the expanding local currency and local currency denominated debt market. Corporate debt focuses on the developing corporate debt asset class. Blended debt mandates specifically combine external, local currency and corporate debt measured against tailor-made blended indices. Multi-strategy is a dynamic asset allocation across other investment themes. Equities Focuses on liquidity and top down macro country selection in publicly traded. Overlay/liquidity helps to separate and centralize the currency risk of an underlying emerging market asset class. Advisors' Opinion:
  • [By Inyoung Hwang]

    Ashmore Group Plc (ASHM) jumped 5.3 percent to 382.2 pence. The U.K. fund manager that invests in emerging markets reported full-year pretax profit and revenue that exceeded estimates. The London-based company also raised its dividend.

Top Integrated Utility Stocks To Invest In Right Now: Sterling Consolidated Corp (STCC)

Sterling Consolidated Corp., incorporated on January 31, 2011, is a holding company. The Company�� operations are conducted through its four subsidiaries: Sterling Seal & Supply, Inc. (Sterling Seal), ADDR Properties, LLC (ADDR), Q5 Ventures, LLC (Q5), and Integrity Cargo Freight Corporation (Integrity). The Company through its subsidiary, Sterling Seal engages primarily in the distribution and sale of O-rings, rubber seals, oil seals, custom molded rubber parts, custom Teflon parts, Teflon rods, O-ring cord, bonded seals, O-ring kits, and stuffing box sealant. The Company also owns real property through its subsidiaries ADDR and Q5. In addition, the Company�� subsidiary Integrity Cargo Freight Corporation (Integrity) is a freight forwarding business. In September 2013, the Company announced the acquisition of Superior Seals and Service in High Point, NC.

Sterling Seal sells directly to smaller distributors and original equipment manufacturers in need of seals. It offers a catalogue of standard sizes, and will take orders for special sizes not available in the standard catalogue. O-rings and the other products that Sterling Seal sells are used in a variety of industries, including automotive, pump, transmissions, oil and energy, machinery, and packaging. Integrity are primarily responsible for transporting products the Company order from its suppliers back to its warehouse in Neptune, NJ. After Sterling Seal confirms from its supplier that a product is ready to be picked up, Integrity Cargo is responsible for picking up the products and getting them to the dock and delivered to the Sterling Seal warehouse. ADDR owns a 28,000 square foot facility in Neptune, NJ. Q5 Ventures, LLC owns a 5,000 square foot facility in Apopka, Florida, which is used by Sterling Seal for its Florida operations.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap stocks Muscle Warfare International (OTCMKTS: MWAR), Portlogic Systems Inc (OTCMKTS: PGSY) and Sterling Consolidated Corp (OTCBB: STCC) were all the subject of a few paid promotions as recently as last week but they sure did not start the new week out right because all were sinking on Monday. So are these small cap stocks that are either the subject of promotions or investor awareness campaigns hot or not? Here is a quick reality check:

  • [By Peter Graham]

    Small cap stocks Pulse Network Inc (OTCBB: TPNI), Sterling Consolidated Corp (OTCBB: STCC) and diaDexus, Inc (OTCMKTS: DDXS) have or could start to sizzle for investors. However, I should also mention that two of these stocks have been the subject of paid promotions while a third apparently has not been, and could be the real deal. With that in mind, here is a closer look along with a quick reality check about all three small caps to help you decide whether they are hot or not:

Top Integrated Utility Stocks To Invest In Right Now: Western Gas Partners LP (WES)

Western Gas Partners, LP (the Partnership) is a master limited partnership (MLP) organized by Anadarko Petroleum Corporation to own, operate, acquire and develop midstream energy assets. The Partnership operates in East and West Texas, the Rocky Mountains (Colorado, Utah and Wyoming) and the Mid-Continent (Kansas and Oklahoma) and are engaged primarily in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, natural gas liquids (NGLs) and crude oil for Anadarko and third-party producers and customers. As of December 31, 2011, the Company�� assets consist of 11 gathering systems, seven natural gas treating facilities, seven natural gas processing facilities, one NGL pipeline, one interstate pipeline, and interests in a gas gathering system and a crude oil pipeline. Its assets are located in East and West Texas, the Rocky Mountains (Colorado, Utah and Wyoming), and the Mid-Continent (Kansas and Oklahoma). In August 2012, it has acquired an additional 24% membership interest in Chipeta Processing LLC from Anadarko Petroleum Corporation.

On January 13, 2012, the Partnership completed the acquisition of Anadarko�� 100% ownership interest in Mountain Gas Resources, LLC, which owns the Red Desert Complex (Red Desert), a 22% interest in Rendezvous Gas Services, LLC (Rendezvous) and related facilities. Red Desert includes the Patrick Draw processing plant, the Red Desert processing plant, 1,295 miles of gathering lines and related facilities. Rendezvous owns a 338-mile mainline gathering system serving the Jonah and Pinedale Anticline fields in south-western Wyoming, which delivers gas to the Granger complex and other locations. In July 8, 2011, the Company acquired the Bison gas treating facility from Anadarko. In February 28, 2011, it acquired a natural gas gathering system and cryogenic gas processing facilities, collectively referred to as the Platte Valley assets, financed with borrowings under its revolving credit facility. On February 28,! 2011, Kerr-McGee Gathering LLC, a wholly owned subsidiary of Western Gas Partners, LP (the Partnership), acquired midstream assets from Encana Oil & Gas (USA) Inc. These assets are located in the Denver-Julesburg Basin, northeast of Denver, Colorado, and consist of an approximately 1,054-mile natural gas gathering system and related compression and other ancillary equipment, and gas processing facilities with current cryogenic capacity of 84 one million cubic feet per day.

Rocky Mountains

The Bison treating facility consists of three amine treaters with a combined treating capacity of 450 million cubic feet per day located in the north-eastern corner of Wyoming. The assets also include three compressors with a combined compression of 5,230 horsepower and five generators with combined power output of 6.5 megawatts. The Company operates and has a 100% working interest in the Bison assets, which provide carbon dioxide (CO2) treating services for the coal-bed methane gas gathered in the Powder River Basin. During the year ended December 31, 2011, Anadarko provided approximately 73% of the throughput at the Bison treating facility, and the remaining throughput was from one third-party producer. The Bison treating facility treats and compresses gas from the coal-bed methane wells in the Powder River Basin. The Bison Pipeline, operated by TransCanada, is connected directly to the facility, which is the only inlet into the pipeline. The Bison treating facility also has access to the Ft. Union and Thunder Creek pipelines.

The Company is the managing member of Chipeta, a limited liability company owned by the Partnership (51%), Ute Energy Midstream Holdings LLC (25%) and Anadarko (24%). The Chipeta complex includes a natural gas processing plant with two processing trains, the Natural Buttes plant, and a 100% Partnership-owned 17-mile natural gas liquid (NGL) pipeline connecting the Chipeta plant to a third-party pipeline. The Chipeta assets has cryogenic and refrigeration ! processin! g capacity of 670 million cubic feet per day. These assets provide processing and transportation services in the Greater Natural Buttes area in Uintah County, Utah. During 2011, Chipeta began construction of a second cryogenic train at the Chipeta plant with processing capacity of approximately 300 million cubic feet per day. During 2011, Anadarko is a customer on the Chipeta system with approximately 94% of the system throughput. The Chipeta system has access to Anadarko and third-party production in the area with excess available capacity in the Uintah Basin. Anadarko controls approximately 217,000 gross acres in the Uintah Basin. Chipeta is connected to both Anadarko�� Natural Buttes gathering system and to the Three Rivers gathering system owned by Ute Energy and a third party. The Chipeta plant delivers NGLs through its 17-mile pipeline to the Mid-America Pipeline (MAPL), which provides transportation through the Seminole pipeline in West Texas and ultimately to the NGL markets at Mont Belvieu, Texas and the Texas Gulf Coast. The Chipeta plant has natural gas delivery points through the pipelines, which includes Colorado Interstate Gas Company (CIG), Questar Pipeline Company�� pipeline, and Wyoming Interstate Company, Ltd.

The 47-mile Clawson gathering system, located in Carbon and Emery Counties of Utah, to provide gathering services for Anadarko�� coal-bed methane development of the Ferron Coal play. The Clawson gathering system provides gathering, dehydration, compression and treating services for coal-bed methane gas. The Clawson gathering system includes one compressor station, with 6,310 horsepower, and a CO2 treating facility. During 2011, Anadarko is the shipper on the Clawson gathering system with approximately 97% of the total throughput delivered into the system, and the remaining throughput on the system was from one third-party producer. Clawson Springs Field has approximately 7,000 gross acres and produces primarily from the Ferron Coal play. The Clawson gathering s! ystem del! ivers into Questar Transportation Services Company�� pipeline. The Fort Union system is a 324-mile gathering system operating within the Powder River Basin of Wyoming, starting in west central Campbell County and terminating at the Medicine Bow treating plant. The Fort Union gathering system consists of three parallel pipelines and includes CO2 treating facilities at the Medicine Bow plant. At CO2 levels, the system is capable of treating and blending over one billion cubic feet per day while satisfying the CO2 specifications of downstream pipelines. Fort Union Gas Gathering, LLC is a partnership among Copano Pipelines/Rocky Mountains, LLC (37.04%), Crestone Powder River LLC (37.04%), Bargath, Inc. (11.11%) and the Partnership (14.81%). Anadarko is the field and construction operator of the Fort Union gathering system. The NGLs have market access to Enterprise�� Mid-America Pipeline Company (MAPCO), which terminates at Mont Belvieu, Texas, as well as to local markets.

The 810-mile natural gas gathering system and gas processing facility is located in Sweetwater County, Wyoming. The Granger system includes eight field compression stations with 41,950 horsepower. The processing facility has a cryogenic capacity of 200 million cubic feet per day and refrigeration capacity of 100 million cubic feet per day with NGL fractionation. During 2011, Anadarko is the customer on the Granger system with approximately 54% of throughput, and the remaining throughput was primarily from five third-party shippers. The Granger system is supplied by the Moxa Arch, the Jonah field and the Pinedale anticline across, which Anadarko controls approximately 568,000 gross acres. The Granger gas gathering system has approximately 690 receipt points. The residue gas from the Granger system can be delivered to the pipelines, which includes CIG, Kern River and Mountain Gas Transportation, Inc (MGTI) pipelines through a connect with Rendezvous Pipeline Company, Northwest Pipeline Co (NWPL), Overthrust Pipeline OTTCO, a! nd Questa! r Gas Management Company (QGM).

The 67-mile Helper gathering system, located in Carbon County, Utah, built to provide gathering services for Anadarko�� coal-bed methane development of the Ferron Coal play. The Helper gathering system provides gathering, dehydration, compression and treating services for coal-bed methane gas. The Helper gathering system includes two compressor stations with a combined 14,075 horsepower and two CO2 treating facilities. Anadarko is the shipper on the Helper gathering system. The Helper Field and Cardinal Draw Fields are Anadarko-operated coal-bed methane developments on the south-western edge of the Uintah Basin that produce from the Ferron Coal play. The Helper Field covers approximately 19,000 acres as of December 31, 2011 and Cardinal Draw Field, which lies immediately to the east of Helper Field, also covers approximately 20,000 acres. The Helper gathering system delivers into the Questar Transportation Services Company�� pipeline. Questar provides transportation to regional markets in Wyoming, Colorado and Utah and also delivers into the Kern River Pipeline, which provides transportation to markets in the western United States, primarily California.

The 1,056-mile Hilight gathering system, located in Johnson, Campbell, Natrona and Converse Counties of Wyoming, built to provide low and high-pressure gathering services for the area�� conventional gas production and delivers to the Hilight plant for processing. The Hilight gathering system has 11 compressor stations with 32,263 combined horsepower. The Hilight system has a capacity of approximately 30 million cubic feet per day and utilizes a refrigeration process and provides for fractionation of the recovered NGL products into propane, butanes and natural gasoline. Gas gathered and processed through the Hilight system is from numerous third-party customers, with the nine producers providing approximately 75% of the system throughput during 2011. The Hilight gathering system serves the g! as gather! ing needs of several conventional producing fields in Johnson, Campbell, Natrona and Converse Counties. The Hilight plant delivers residue gas into its MIGC transmission line.

The MIGC system is a 256-mile interstate pipeline regulated by FERC and operating within the Powder River Basin of Wyoming. The MIGC system traverses the Powder River Basin from north to south, extending to Glenrock, Wyoming. The MIGC system is well positioned to provide transportation for the natural gas volumes received from various coal-bed methane gathering systems and conventional gas processing plants throughout the Powder River Basin. MIGC offers both forward-haul and backhaul transportation services and is certificated for 175 million cubic feet per day of firm transportation capacity. During 2011, Anadarko is the firm shipper on the MIGC system, with approximately 86% of throughput, with the remaining throughput from 11 third-party shippers. As of December 31, 2011, Anadarko has a working interest in over 1.7 million gross acres within the Powder River Basin. Anadarko�� gross acreage includes substantial undeveloped acreage positions in the expanding Big George coal play and the multiple seam coal fairway to the north of the Big George play. MIGC volumes are redelivered to the Glenrock, Wyoming Hub, which accesses the interstate pipelines, which includes CIG, Kinder Morgan Interstate Gas Transportation Company, Williston Basin Interstate Pipeline Company, and Wyoming Interstate Gas Company. Volumes are also delivered to Anadarko�� MGTC, Inc. (MGTC) intrastate pipeline, a Hinshaw pipeline that supplies local markets in Wyoming.

The 179-mile Newcastle gathering system, located in Weston and Niobrara Counties of Wyoming, was built to provide gathering services for conventional gas production in the area. The gathering system delivers into the Newcastle plant, which has gross capacity of approximately two million cubic feet per day. The plant utilizes a refrigeration process and provides for frac! tionation! of the recovered NGLs into propane and butane/gasoline mix products. The Newcastle facility is a joint venture among Black Hills Exploration and Production, Inc. (44.7%), John Paulson (5.3%) and the Partnership (50.0%). The Newcastle gathering system includes one compressor station with 560 horsepower. The Newcastle plant has an additional 2,100 horsepower for refrigeration and residue compression. Gas gathered and processed through the Newcastle system is from 12 third-party customers, with the four producers providing approximately 92% of the system throughput during 2011. The producer, Black Hills Exploration, provided approximately 62% of the throughput during 2011. The Newcastle gathering system and plant primarily service gas production from the Clareton and Finn-Shurley fields in Weston County. Propane products from the Newcastle plant are typically sold locally by truck, and the butane/gasoline mix products are transported to the Hilight plant for further fractionation. Residue gas from the Newcastle system is delivered into Anadarko�� MGTC pipeline for transport, distribution and sale.

The Platte Valley system, located in the Denver-Julesburg Basin, consists of a processing plant with current cryogenic capacity of 100 million cubic feet per day, two fractionation trains, a 1,099-mile natural gas gathering system and related equipment. The Platte Valley gathering system has 13 compressor stations with a combined 17,011 of operating horsepower. During 2011, approximately 8% of the Platte Valley system throughput was from Anadarko and the remaining throughput was from various third-party customers, the EnCana Corporation. There are 713 receipt points connected to the Platte Valley gathering system as of December 31, 2011. The system is connected to its Wattenberg gathering system. The Platte Valley system is primarily supplied by the Wattenberg field and covers portions of Adams, Arapahoe, Boulder, Broomfield, Denver, Elbert, and Weld Counties, Colorado. The Platte Valley system de! livers NG! Ls through the pipelines, which includes local markets, ONEOK Overland Pass Pipeline, and the Wattenberg Pipeline owned and operated by DCP Midstream (formerly the Buckeye Pipeline). In addition, the Platte Valley system can deliver to the CIG and Xcel Energy residue gas pipelines.

The Wattenberg gathering system is a 1,781-mile wet gas gathering system in the Denver-Julesburg Basin, north and east of Denver, Colorado, and includes six compressor stations and combined 72,579 of operating horsepower. The Fort Lupton processing plant has two trains with combined processing capacity of 105 million cubic feet per day. During 2011, Anadarko-operated production represented approximately 66% of system throughput. Approximately 29% of Wattenberg system throughput was from two third-party producers and the remaining throughput was from various third-party customers. There are 2,129 receipt points and over 5,900 wells connected to the gathering system as of December 31, 2011. The Wattenberg gathering system is primarily supplied by the Wattenberg field and covers portions of Adams, Arapahoe, Boulder, Broomfield and Weld counties. Anadarko controls approximately 762,000 gross acres in the Wattenberg field. Anadarko drilled 472 wells and completed 2,090 fracs at the Wattenberg field during 2011, and had identified 1,200 to 2,700 opportunities to increase production, including new well locations, re-fracs and recompletions. The Wattenberg gathering system has five delivery points, with the primary delivery points, which includes Anadarko�� Wattenberg processing plant, Fort Lupton processing plant, and Platte Valley processing plant.

The White Cliffs pipeline consists of a 526-mile crude oil pipeline that originates in Platteville, Colorado and terminates in Cushing, Oklahoma. It has an approximate capacity of 80,000 barrels per day. At the point of origin, it has a 100,000-barrel storage facility and a truck-loading facility with an additional 220,000 barrels of storage. The pipeline is a! joint ve! nture owned by SemCrude Pipeline LP (51%), Plains Pipeline LP (34%), Noble Energy, Inc. (5%) and the Partnership (10%). The White Cliffs pipeline has two throughput contracts with Anadarko and Noble Energy. During 2011, Anadarko was the shipper on the White Cliffs pipeline. The White Cliffs pipeline is supplied by production from the Denver-Julesburg Basin and is the only direct route from the Denver-Julesburg Basin to Cushing, Oklahoma. The White Cliffs pipeline delivery point is SemCrude�� storage facility in Cushing, Oklahoma, a major crude oil marketing center, which ultimately delivers to the mid-continent refineries.

Mid-Continent

The 1,953-mile Hugoton gathering system provides gathering service to the Hugoton field and is primarily located in Seward, Stevens, Grant and Morton Counties of Southwest Kansas and Texas County in Oklahoma. The Hugoton gathering system has 44 compressor stations with a combined 92,097 horsepower of compression. Anadarko is the customer on the Hugoton gathering system with approximately 76% of the system throughput, during 2011. During 2011, approximately 19% of the throughput on the Hugoton system was from one third-party shipper with the balance from various other third-party shippers. The Hugoton field is a natural gas fields in North America. The Hugoton gathering system is connected to DCP Midstream�� National Helium plant, which extracts NGLs and helium and delivers residue gas into the Panhandle Eastern pipeline. The system is also connected to the Satanta plant, which is owned by Pioneer Natural Resources Corporation (51%) and Anadarko (49%), for NGLs and helium processing and delivers residue gas into Kansas Gas Services and Southern Star pipeline.

East Texas

The 323-mile Dew gathering system is located in Anderson, Freestone, Leon and Robertson Counties of East Texas. The Dew gathering system has 10 compressor stations with a combined 36,175 horsepower of compression. Anadarko is the only shipper on the ! Dew gathe! ring system. As of December 31, 2011, Anadarko has approximately 833 producing wells in the Bossier play and controls approximately 122,000 gross acres in the area. The Dew gathering system has delivery points with Pinnacle Gas Treating LLC, which is the primary delivery point and is described in more detail below, and Kinder Morgan�� Tejas pipeline.

The Pinnacle gathering system includes the Partnership�� 266-mile Pinnacle gathering system and its Bethel treating plant. The Pinnacle system provides sour gas gathering and treating service in Anderson, Freestone, Leon, Limestone and Robertson Counties of East Texas. The Bethel treating plant, located in Anderson County, has total CO2 treating capacity of 502 million cubic feet per day and 20 long tons per day of sulfur treating capacity. During 2011, Anadarko was shipper on the Pinnacle gathering system with approximately 90% of system throughput and the remaining throughput on the system was from four third-party shippers. The Pinnacle gathering system provide gathering and treating services to the five-county area over, which it extends, including the Cotton Valley Lime formations, which contain concentrations of sulfur and CO2. The Pinnacle gathering system is connected to Atmos Texas pipeline, Enbridge Pipelines (East Texas) LP pipeline, Energy Transfer Fuels pipeline, Enterprise Texas Pipeline, LP�� pipeline, ETC Texas Pipeline, Ltd pipeline, and Kinder Morgan�� Tejas pipeline. These pipelines provide transportation to the Carthage, Waha and Houston Ship Channel market hubs in Texas.

West Texas

The 118-mile Haley gathering system provides gathering and dehydration services in Loving County, Texas and gathers a portion of Anadarko�� production from the Delaware Basin. During 2011, Anadarko�� production represented approximately 69% of the Haley gathering system�� throughput, and the remaining throughput is attributable to Anadarko�� partner in the Haley area. As of December 31, 2011, in the great! er Delawa! re basin, Anadarko has access to approximately 355,000 gross acres, is a portion of which is gathered by the Haley gathering system. The Haley gathering system has multiple delivery points. The primary delivery points are to the El Paso Natural Gas pipeline or the Enterprise GC, LP pipeline for delivery into Energy Transfer�� Oasis pipeline. It also delivers into Southern Union Energy Services��pipeline for further delivery into the Oasis pipeline. The pipelines at these delivery points provide transportation to both the Waha and Houston Ship Channel markets.

The Company competes with QEP Field Services Company, El Paso Midstream Group, Inc., XTO Energy, ETC Texas Pipeline, Ltd, Enbridge Pipelines (East Texas) LP, Kinder Morgan Tejas Pipeline, LP, MIGC, Thunder Creek Gas Services, Williston Basin Interstate Pipeline Company, TransCanada, Williams Field Services, Enterprise Gas Processing, LLC, Jonah Gas Gathering Company, QEP Field Services Company, Anadarko�� Delaware Basin JV Gathering LLC, Enterprise GC, LP, Targa Midstream Services LLC, Southern Union Energy Services Company, DCP Midstream, Merit Energy, ONEOK Gas Gathering Company, Pioneer Natural Resources and AKA Energy.

Advisors' Opinion:
  • [By David Fickling]

    Wesfarmers Ltd. (WES), Australia�� largest private-sector employer, fell the most in more than two years in Sydney trading after it said earnings from its Target department stores would drop as much as 43 percent from a year earlier.

  • [By Anna Prior]

    Anadarko Petroleum Corp.(APC) said it has taken steps to improve its financial flexibility, including paring its stake in the company that manages natural-gas and crude-oil unit Western Gas Partners LP(WES). Anadarko said it made $335 million in cash on the offering. Anadarko shares rose 2.9% to $109.00 premarket.

Top Integrated Utility Stocks To Invest In Right Now: Warner Chilcott plc(WCRX)

Warner Chilcott Public Limited Company, a specialty pharmaceutical company, together with its subsidiaries, engages in the development, manufacture, and promotion of branded pharmaceutical products focusing on the women?s healthcare, gastroenterology, dermatology, and urology markets in North America and western Europe. Its principal products include ACTONEL for the prevention and treatment of postmenopausal osteoporosis; ATELVIA for the treatment of postmenopausal osteoporosis; LOESTRIN 24 FE and LO LOESTRIN FE, which are oral contraceptives for the prevention of pregnancy; ESTRACE cream, a vaginal cream for the treatment of vaginal and vulvar atrophy; ASACOL for the treatment of ulcerative colitis for orally administered 5-aminosalicylic acid products and maintenance of remission; ASACOL HD for the treatment of moderately active ulcerative colitis; DORYX, a tetracycline-class oral antibiotic for the treatment of severe acne; and ENABLEX for the treatment of overactive b ladder. The company markets its products and services through wholesale pharmaceutical distributors, and retail drug store chains. It has a strategic collaboration agreement with Sanofi-Aventis U.S. LLC. Warner Chilcott Public Limited Company was founded in 1968 and is headquartered in Dublin, Ireland.

Advisors' Opinion:
  • [By Sean Williams]

    What: Shares of Warner Chilcott (NASDAQ: WCRX  ) , a branded pharmaceutical company focused on women's health care, shot higher by as much as 20% after the company reported its first-quarter earnings results, and on news that it could be a buyout target.

Monday, July 28, 2014

Best Value Stocks To Buy Right Now

Best Value Stocks To Buy Right Now: Tupperware Corporation(TUP)

Tupperware Brands Corporation operates as a direct seller of various products across a range of brands and categories through an independent sales force. The company engages in the manufacture and sale of kitchen and home products, and beauty and personal care products. It offers preparation, storage, and serving solutions for the kitchen and home, as well as kitchen cookware and tools, children?s educational toys, microwave products, and gifts under the Tupperware brand name primarily in Europe, Africa, the Middle East, the Asia Pacific, and North America. The company provides beauty and personal care products, which include skin care products, cosmetics, bath and body care, toiletries, fragrances, nutritional products, apparel, and related products principally in Mexico, South Africa, the Philippines, Australia, and Uruguay. It offers beauty and personal care products under the Armand Dupree, Avroy Shlain, BeautiControl, Fuller, NaturCare, Nutrimetics, Nuvo, and Swissgar de brand names. The company sells its Tupperware products directly to distributors, directors, managers, and dealers; and beauty products primarily through consultants and directors. As of December 26, 2009, the Tupperware distribution system had approximately 1,800 distributors, 61,300 managers, and 1.3 million dealers; and the sales force representing the Beauty businesses approximately 1.1 million. The company was formerly known as Tupperware Corporation and changed its name to Tupperware Brands Corporation in December 2005. The company was founded in 1996 and is headquartered in Orlando, Florida.

Advisors' Opinion:
  • [By James Brumley]

    CSCO stock might be one of the market’s dark-horse stories of 2014; the dividend yield is the icing on the cake.

    Dividend Stocks to Buy: Tupperware Brands (TUP)

    Dividend Yield: 3.2%

  • [By Ben Levisohn]

    Shares of Herbalife have gained 0.9% to $79.51 this m! orning in pre-open trading. Its shares have gained 139% this year, a nice gain, but lagging Nu Skin Enterprises 271% rise. Avon Products(AVP), another multi-level marketer, has gained 21% so far this year, while Tupperware Brands(TUP) has risen 49%.

  • [By Dan Caplinger]

    Where growth will come from
    One area that Newell Rubbermaid still has to tap fully is emerging markets. The company has done a good job of expanding overseas, with 17% annual growth in Latin America. But with barely a quarter of its sales coming from outside the U.S. and Canada, the company has a lot further to go. Storage rival Tupperware (NYSE: TUP  ) gets fully 60% of its total revenue from emerging markets, and it too has seen impressive gains in South America as well as the Asia-Pacific region.

  • source from Top Penny Stocks For 2015:http://www.topstocksforum.com/best-value-stocks-to-buy-right-now.html

Sunday, July 27, 2014

5 Best Paper Stocks To Invest In 2014

Ray Dalio is the founder of the world's largest and best-performing hedge fund in 2011, Bridgewater Associates. The letter was created October 31, 2008 and updated March, 2012:

The economy is like a machine. At the most fundamental level it is a relatively simple machine, yet it is not well understood. I wrote this paper to describe how I believe it works. My description is not the same as conventional economists' descriptions so you should decide for yourself whether or not what I'm saying makes sense. I will start with the simple things and build up, so please bear with me. I believe that you will be able to understand and assess my description if we patiently go through it.

How the Economic Machine Works: "A Transactions-Based Approach"

An economy is simply the sum of the transactions made and a transaction is a simple thing. A transaction consists of the buyer giving money (or credit) to a seller and the seller giving a good, a service or a financial asset to the buyer in exchange. A market consists of all the buyers and sellers making exchanges for the same things ��e.g., the wheat market consists of different people making different transactions for different reasons over time. An economy consists of all of the transactions in all of its markets. So, while seemingly complex, an economy is really just a zillion simple things working together, which makes it look more complex than it really is.

Top 10 Blue Chip Stocks To Watch Right Now: Domtar Corp (UFS)

Domtar Corporation, incorporated on August 16, 2006, designs, manufactures, markets and distributes a range of fiber-based products, including communication papers, specialty and packaging papers and adult incontinence products. The Company operates in three business segments: Pulp and Paper, Distribution and Personal Care. Its Pulp and Paper segment consists of the manufacturing, sale and distribution of communication, specialty and packaging papers, as well as softwood, fluff and hardwood market pulp. The Company�� Distribution segment includes the purchasing, warehousing, sale and distribution of its paper products and those of other manufacturers. These products include business and printing papers, certain industrial products and printing supplies. Its Personal Care segment consists of the manufacturing, sale and distribution of adult incontinence products.The Company is an integrated marketer and manufacturer of uncoated freesheet paper in North America for a variety of customers, including merchants, retail outlets, stationers, printers, publishers, converters and end-users. The Company produces incontinence care products marketed primarily under the Attends brand. The Company owns and operates Ariva. On May 10, 2012, the Company acquired EAM Corporation. In June 2013, the Company announced the completion of its acquisition of Xerox Corp paper and print media products business in the United States and Canada. In July 2013, Domtar Corp announced that completion of the acquisition of Associated Hygienic Products (AHP) from DSG International. In January 2014, the Company acquired Laboratorios Indas, SAU.

Pulp and Paper

The Company produces 4.2 million metric tons of hardwood, softwood and fluff pulp at 12 of its 13 mills. The majority of its pulp is consumed internally to manufacture paper and consumer products, with the balance being sold as market pulp. The Company also purchases papergrade pulp from third parties. The Company has 10 pulp and paper mills (eight in the! United States and two in Canada), with an annual paper production capacity of approximately 3.4 million tons of uncoated freesheet paper. Its paper manufacturing operations are supported by 15 converting and distribution operations, including a network of 12 plants located offsite of its paper making operations. In addition, it has forms manufacturing operations at three offsite converting and distribution operations. Approximately 81% of its paper production capacity is in the United States, and the remaining 19% is located in Canada.

The Company produces market pulp in excess of its internal requirements at its three non-integrated pulp mills in Kamloops, Dryden, and Plymouth, as well as at its pulp and paper mills in Espanola, Ashdown, Hawesville, Windsor, Marlboro and Nekoosa. The Company sells approximately 1.6 million metric tons of pulp per year depending on market conditions. Approximately 50% of its trade pulp production capacity is in the United States, and the remaining 50% is located in Canada. The fiber used by its pulp and paper mills in the United States is hardwood and softwood, both being readily available in the market from multiple third-party sources. The fiber used at its Windsor pulp and paper mill is hardwood originating from a variety of sources, including purchases on the open market in Canada and the United States, contracts with Quebec wood producers��marketing boards, public land where it has wood supply allocations and from its private lands. The softwood and hardwood fiber for its Espanola pulp and paper mill and the softwood fiber for its Dryden pulp mill, is obtained from third parties, directly or indirectly from public lands, through designated wood supply allocations for the pulp mills. The fiber used at the Company�� Kamloops pulp mill is all softwood, originating from third-party sawmilling operations in the southern-interior part of British Columbia.

The Company uses various chemical compounds in its pulp and paper manufacturing facili! ties that! it purchases, primarily on a central basis, through contracts. For pulp manufacturing, it uses numerous chemicals, including caustic soda, sodium chlorate, sulfuric acid, lime and peroxide. For paper manufacturing, it also uses several chemical products, including starch, precipitated calcium carbonate, optical brighteners, dyes and aluminum sulfate. It owns power generating assets, including steam turbines, at all of its integrated pulp and paper mills, as well as hydro assets at four locations: Espanola, Ottawa-Hull, Nekoosa and Rothschild. The Company�� business papers include copy and electronic imaging papers, which are used with ink jet and laser printers, photocopiers and plain-paper fax machines, as well as computer papers, preprinted forms and digital papers. These products are primarily for office and home use. The Company�� commercial printing and publishing papers include uncoated freesheet papers, such as offset papers and opaques. These uncoated freesheet grades are used in sheet and roll fed offset presses across the spectrum of commercial printing end-uses, including digital printing. Its publishing papers include tradebook and lightweight uncoated papers used primarily in book publishing applications, such as textbooks, dictionaries, catalogs, magazines, hard cover novels and financial documents. Design papers, a sub-group of commercial printing and publishing papers, have features of color, brightness and texture and are targeted towards graphic artists, design and advertising agencies, primarily for special brochures and annual reports. These products also include base papers that are converted into finished products, such as envelopes, tablets, business forms and data processing/computer forms.

The Company also produces paper for several specialty and packaging markets. These products consist primarily of base stock for thermal printing, flexible packaging, food packaging, medical gowns and drapes, sandpapers backing, carbonless printing, labels and other coating a! nd lamina! ting applications. The Company also manufactures papers for industrial and specialty applications, including carrier papers, treated papers, security papers and specialized printing and converting applications. The Company sells business papers primarily to paper stationers, merchants, office equipment manufacturers and retail outlets. The Company distributes uncoated commercial printing and publishing papers to end-users and commercial printers, mainly through paper merchants, as well as selling directly to converters. The Company sells its specialty and packaging papers mainly to converters, who apply a further production process, such as coating, laminating, folding or waxing to its papers before selling them to a variety of specialized end-users.

Distribution

The Company's Distribution business involves the purchasing, warehousing, sale and distribution of the Company's various products and those of other manufacturers. These products include business, printing and publishing papers and certain packaging products. These products are sold to diverse customer base, which includes small, medium and large commercial printers, publishers, quick copy firms, catalog and retail companies and institutional entities. The Company's Distribution business operates in the United States and Canada under a single banner and umbrella name, Ariva. Ariva operates throughout the Northeast, Mid-Atlantic and Midwest areas from 16 locations in the United States, including 12 distribution centers serving customers across North America.

Personal Care

The Company's Personal Care business sells and manufactures adult incontinence products and distributes disposable washcloths marketed primarily under the Attends brand name. The Company is a supplier of adult incontinence products sold into North America and Northern Europe, selling to hospitals (acute cares) and nursing homes (long-term care) and the Company has a growing presence in the homecare and retail channels. The C! ompany op! erates two manufacturing facilities, with each having the ability to produce multiple product categories. The Company also has a research and development facility and production lines which manufacture high quality airlaid and ultrathin laminated absorbent cores.

Advisors' Opinion:
  • [By Rich Duprey]

    Specialty paper maker�Domtar� (NYSE: UFS  ) �wrote it all down yesterday: it�will pay a�regular quarterly dividend�of $0.55 per share that's 22% higher than the $0.45 per share payout it made last quarter. Shareholders of record on June 14 will receive the new dividend rate at the close of business on July 15.

5 Best Paper Stocks To Invest In 2014: Fibria Celulose SA (FIBR3)

Fibria Celulose SA, formerly Votorantim Celulose e Papel SA, is a Brazil-based company involved in the production and sale of short fiber pulp. The Company operates pulp manufacturing plants in Aracruz (Espirito Santo), Tres Lagoas (Mato Grosso do Sul), Jacarei (Sao Paulo) and Veracel (Bahia). Additionally, the Company is engaged in the cultivation of eucalyptus. It has plantations in the Brazilian states of Sao Paulo, Minas Gerais, Rio de Janeiro, Mato Grosso do Sul, Bahia and Espirito Santo. In 2011, the Company sold a business unit active in paper production. The Company has a number of subsidiaries in Brazil and abroad, including Normus Empreendimentos e Participacoes Ltda, Fibria Overseas Finance Ltd and Fibria Celulose (USA) Inc, among others. On October, 2013, the Company announced merger by incorporation of Normus Empreendimentos e Participacoes Ltda, a wholly-owned subsidiary of the Company, in order to simplify the corporate structure. Advisors' Opinion:
  • [By Harry Suhartono]

    The Ibovespa dropped 1.8 percent as iron-ore producer Vale SA (VALE5), whose main export market is China, snapped a two-day gain. Pulp producer Fibria Celulose SA (FIBR3) retreated after posting quarterly earnings that trailed analysts��estimates. Brazil plans to sell dollar bonds due in 2025, creating a new benchmark security in international markets, and buy back notes maturing in as little as four years.

  • [By Julia Leite]

    Fibria Celulose SA (FIBR3), the world�� largest pulp producer, climbed after settling a tax dispute with Brazil over profits at its foreign units. Iron-ore producer Vale SA (VALE5) gained before a report due this weekend forecast to show manufacturing is still expanding in China, the company�� main export market.

5 Best Paper Stocks To Invest In 2014: Cornerstone Progressive Return Fund(CFP)

Cornerstone Progressive Return Fund is a closed-ended equity fund of fund launched and managed by Cornerstone Advisors, Inc. The fund invests funds investing in the public equity markets of the United States. It invests in stocks of companies operating across diversified sectors. Cornerstone Progressive Return Fund was formed on April 26, 2007 and is domiciled in the United States.

Advisors' Opinion:
  • [By Dan Caplinger]

    But you can see in several places the consequences of the stampede toward high yield. Here are just a few:

    Closed-end funds Cornerstone Progressive (NYSEMKT: CFP  ) and Pimco High Income (NYSE: PHK  ) both make fixed payments back to fund shareholders on a monthly basis, and their distribution yields are truly extraordinary, at about 17% and 12%, respectively. Those dividends have enticed shareholders to pay $1.30 to $1.40 or more for each $1 of assets in the funds. Yet during most months, a substantial portion of those distribution payments has simply been a return of investor capital rather than true income from the funds' investments. A recent study discussed in The Wall Street Journal found that returns on a portfolio with a combined value and dividend-income strategy outperformed a strategy focused more exclusively on maximizing dividends by an average of 1.7 percentage points per year, a huge edge in long-run returns. In the dividend ETF arena, most funds tend to focus on maximizing yield. Although the popular Vanguard Dividend Appreciation (NYSEMKT: VIG  ) ETF bucks the trend by screening first for consistent dividend growth and only then looking at yield as a factor, many rival ETFs start with high-yielding stocks as their baseline and only then consider other desirable traits. Others focus solely on high-dividend niches of the market, such as iShares FTSE NAREIT Mortgage-Plus (NYSEMKT: REM  ) and its concentration on high-yield mortgage REITs.

    When dividend stocks get too popular, their prices get out of line with both their dividend income and the fundamentals of the businesses that underlie those stocks. In simpler terms, when dividend stocks become bad values, it's time to consider looking elsewhere for a margin of safety.

5 Best Paper Stocks To Invest In 2014: Greif Inc (GEF)

Greif, Inc., incorporated on January 25, 1926, is a producer of industrial packaging products and services with manufacturing facilities located in over 50 countries. The Company offers a line of industrial packaging products, such as steel, fiber and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and reconditioned containers, and services such as container lifecycle management, blending, filling and other packaging services, logistics and warehousing. It also produces containerboard and corrugated products for niche markets in North America. It sells timber to third parties from its timberland in the south-eastern United States. It has four segments: Rigid Industrial Packaging & Services, Flexible Products & Services, Paper Packaging and Land Management.

Rigid Industrial Packaging and Services

In the Rigid Industrial Packaging and Services, the Company is a provider of rigid industrial packaging products, including steel, fiber and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and reconditioned containers, and services, such as container lifecycle management, blending, filling and other packaging services, logistics and warehousing. It sells industrial packaging products to customers in industries, such as chemicals, paints and pigments, food and beverage, petroleum, industrial coatings, agricultural, pharmaceutical and mineral, among others.

Flexible Products and Services segment

In the Flexible Products and Services segment, the Company is a producer of flexible intermediate bulk containers and a North American provider of industrial and consumer multiwall bag products. Its flexible intermediate bulk containers consist of a polypropylene-based woven fabric that is partly produced at its production sites, as well as sourced from strategic regional sup! pliers. Its industrial and consumer multiwall bag products are used to ship a range of industrial and consumer products, such as seed, fertilizers, chemicals, concrete, flour, sugar, feed, pet foods, popcorn, charcoal and salt, primarily for the agricultural, chemical, building products and food industries.

Paper Packaging segment

In the Paper Packaging segment, the Company sells containerboard, corrugated sheets and other corrugated products to customers in North America in industries such as packaging, automotive, food and building products. Its corrugated container products are used to ship such products as home appliances, small machinery, grocery products, building products, automotive components, books and furniture, as well as numerous other applications. Operations related to industrial and consumer multiwall bag products have been reclassified to Flexible Products and Services segment.

Land Management segment

In the Land Management segment, the Company is focused on the active harvesting and regeneration of the United States timber properties to achieve long-term yields. It also sells, from time to time, timberland and special use land, which consists of surplus land, HBU land and development land. As of October 31, 2013, it owned approximately 252,475 acres of timber property in the southeastern United States and approximately 10,300 acres of timber property in Canada.

Advisors' Opinion:
  • [By Geoff Gannon]

    For those of you wondering if Greif Brothers Cooperage has any relation to Greif (GEF) ��yes. It has every relation. It�� the same exact company. And it�� still in pretty much the same business. They used to just make barrels. Now they make all kinds of different drums, containers, etc. That�� not a very big change for a company to make over 60 years or so.

Saturday, July 26, 2014

Top Biotech Companies To Invest In 2015

On Wednesday,�small cap biotech Arca Biopharma Inc (NASDAQ: ABIO) surged 25.01% on good news about an Investigational New Drug (IND) application only to fall 8.33% on Thursday, meaning investors and traders alike need to�take a closer look at�both the stock and the history of the drug�plus take a look at the performance of biotech benchmarks the�iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).

What is Arca Biopharma?

Small cap Arca Biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases with the�company's lead product candidate being�GencaroTM (bucindolol hydrochloride),�an investigational, pharmacologically unique beta-blocker and mild vasodilator that is being developed for the prevention of atrial fibrillation (��F�� in patients with heart failure and reduced left ventricular ejection fraction ("HFREF"). Arca Biopharma believes Gencaro has the potential to be the first genetically-targeted cardiovascular therapy. In addition,�the company�holds exclusive, worldwide rights to Gencaro, has been granted patents in the�US and Europe for methods of treating various cardiovascular disorders with Gencaro and has collaborated with Medtronic, Inc (NYSE: MDT)�on the Phase 2B portion of GENETIC-AF, the Company�� Phase 2B/3 clinical trial evaluating Gencaro as a potential treatment for AF.

Top Biotech Companies To Invest In 2015: Sanofi(SNY)

sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.

Advisors' Opinion:
  • [By Stephen Simpson, CFA]

    If there's a downside to Lexicon's partnering opportunities, it's that there aren't many obvious partners left. Unless one of the existing companies in the SGLT space chose to abandon an existing partnership, Novo Nordisk, Roche (RHHBY.OB), and Takeda may be the best candidates to partner with Lexicon, and that's the sort of limited pool that can lead to hard bargaining. Sanofi (SNY) may also belong in this pool as well, though. While the company did reach a licensing agreement with Chugai for an SGLT2 inhibitor in Japan, that agreement was limited in scope and the drug does not appear on Sanofi's August 2013 pipeline chart.

  • [By EXPstocktrader]

    "Questcor Pharmaceuticals is a healthcare name that deserves to be on this list, as it generates some of the highest takeover talk on a day-to-day basis of any name today. Benzinga reported earlier this week that there was unconfirmed chatter of interest from Sanofi (SNY), and although it's been linked to some other names, the latest talk has had the strongest legs. Shares of Questcor are up almost 5% in the past week and 28% over the past three months.

  • [By John Buckingham]

    Sanofi (SNY)

    Based in France, Sanofi is a global integrated healthcare company. We like that it has a relatively robust and promising pipeline of new pharmaceuticals, including several that address diseases that have no current treatments.

Top Biotech Companies To Invest In 2015: Actelion Ltd (ATLN.VX)

Actelion Ltd is a Swiss biopharmaceutical holding company that focuses on the discovery, development and commercialization of small molecule drugs. The Company has four approved drugs on the market: Tracleer, an oral dual endothelin receptor antagonist; Veletri, a prostanoid vasodilator; Ventavis, an inhaled formulation of iloprost, and Zavesca, an oral treatment for type 1 Gaucher disease. Furthermore, the Company has a number of compounds various stages of development. The Company operates through a number of worldwide subsidiaries, including Actelion Registration Ltd, which holds marketing authorizations for products marketed in the European Union; Actelion Clinical Research, Inc, engaged in clinical development on behalf of the Company's group; Actelion Re SA, providing insurance solutions for the Company's group and Actelion US Holding Company, engaged in the holding activities of the Company's United States-based units. In September 2013, it acquired Ceptaris Therapeutics, Inc. Advisors' Opinion:
  • [By Victor Selva]

    Forest Laboratories has a current ratio of 2.69% which is higher than the ones registered by Endo International Plc (ENDP), Valeant Pharmaceuticals International (VRX) and Cubist Pharmaceuticals Inc. (CBST). For investors looking for a higher ROE, Allergan Inc. (AGN) and Actelion Ltd. (ATLN.VX) are good options.

Top 5 Oil Stocks To Invest In Right Now: Tekmira Pharmaceuticals Corp (TKMR)

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc. Advisors' Opinion:
  • [By Lisa Levin]

    Tekmira Pharmaceuticals (NASDAQ: TKMR) shares climbed 34.11% to $13.25. The volume of Tekmira Pharmaceuticals shares traded was 2187% higher than normal. Tekmira signed a development agreement with Monsanto (NYSE: MON) on delivery technology for agricultural applications.

Top Biotech Companies To Invest In 2015: Exelixis Inc.(EXEL)

Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer. It focuses on developing Cabozantinib, an inhibitor of tumor growth, metastasis, and angiogenesis that target MET, VEGFR2, and RET, which are key kinases involved in the development and progression of various cancers. The cabozantinib is in Phase III clinical trial for the treatment for medullary thyroid cancer. The company also engages in various clinical programs for cabozantinib focused on the treatment of metastatic castration-resistant prostate cancer, ovarian cancer, breast cancer, renal cell carcinoma, non-small cell lung cancer, hepatocellular cancer, and melanoma. In addition, Exelixis, Inc. involves in developing a portfolio of other novel compounds to address serious unmet medical needs through collaborations with various pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, Genentech, Inc., Boehringer Ingelheim Gm bH, and GlaxoSmithKline and Daiichi Sankyo Company Limited. Its products under development through collaborations include XL475, XL281, XL139, and XL413 inhibitors; ROR antagonists; therapies targeted against LXR, a nuclear hormone receptor implicated in various cardiovascular and metabolic disorders; XL147, XL765, and isoform-selective PI3K inhibitors; XL518, a small-molecule inhibitor of MEK; sphingosine-1-phosphate type 1 receptor; XL880 inhibitor; and therapies targeted against the mineralocorticoid receptor, a nuclear hormone receptor implicated in various cardiovascular and metabolic diseases. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

Advisors' Opinion:
  • [By Jake L'Ecuyer]

    Equities Trading DOWN
    Shares of Exelixis (NASDAQ: EXEL) were down 36.18 percent to $4.11 after the company issued an update on ongoing COMET-1 phase 3 pivotal trial in men with metastatic castration-resistant prostate cancer. Stifel Nicolaus lowered the price target on the stock from $11.00 to $9.00.

  • [By Sean Williams]

    High-risk, high-reward suggestions
    There's an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that's no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it's all up to the drug or devices' effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on.

    Exelixis (NASDAQ: EXEL  ) : In November Exelixis had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small -- somewhere between 500 and 700 people in the U.S. -- the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dealing with bone metastases as a second or third-line treatment. We won't get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong. ImmunoGen (NASDAQ: IMGN  ) : In February, Roche�and ImmunoGen received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen's first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer -- its targeted-antibody payload, or TAP, technology. ImmunoGen's TAP technology works by attaching a toxin -- in this case Roche's Herceptin -- to an antibody, and teaching that antibody to release the to
  • [By Selena Maranjian]

    D. E. Shaw reduced its stake in lots of companies, including Acadia Pharmaceuticals (NASDAQ: ACAD  ) and Exelixis (NASDAQ: EXEL  ) . Acadia has skyrocketed over the past year, rising more than 10-fold, on high hopes for its pimavanserin drug, which treats psychosis in patients with Parkinson's disease. If the drug gains FDA approval, it will enjoy little competition and could be a big winner for Acadia. The company thinks the drug might be effective against psychosis related to Alzheimer's disease as well and is conducting trials for that, too. Acadia is also raising about $100 million via a secondary stock offering to fund ongoing and future trials.

  • [By John Kell var popups = dojo.query(".socialByline .popC"); popups.forEach(func]

    Among the companies with shares expected to actively trade in Wednesday’s session are American Apparel Inc.(APP), Exelixis Inc.(EXEL) and Francesca's Holdings Corp.(FRAN)

Top Biotech Companies To Invest In 2015: Chromadex Corp (CDXC)

Chromadex Corporation, incorporated on June 19, 2008, is a provider of research and quality-control products and services to the natural products industry. The Company�� products are used by customers worldwide in the dietary supplement, food and beverage, cosmetic and pharmaceutical industries. The Company together with its subsidiaries supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of potential attributes, and reference materials, related contract services, technical consulting and ingredients. On December 3, 2012, ChromaDex Inc. acquired Spherix Consulting Inc. The Company�� principal subsidiaries include ChromaDex, Inc., Chromadex Analytics, Inc. and Spherix Consulting, Inc (Spherix).

The Company provides its clients in the food, supplement and pharmaceutical industries with solutions to manage potential health and regulatory risks. Its science-based solutions are for both new and existing products that may be subject to product liability and/or exposed to changing scientific standards or public perceptions; literature evaluations, and design and assessment of pre-clinical and clinical safety testing. It specializes in regulatory submissions for food and dietary supplement ingredients. For its clients involved in drug development within the pharmaceutical industry, the Company provides similar services, as well as risk-based strategies, including intellectual property data and compliance gap identification, due diligence assessments and investigational new drug writing.

Products and Services

The Company offers bulk raw materials for inclusion in dietary supplements, food, beverage and cosmetic products. Through its catalog, it supplies a range of products necessary to conduct quality control of raw materials and consumer products. The Company through Chromadex Analytics, provides a range of contract services ranging from routine contract analysis for the production of dietary sup! plements, cosmetics, foods and other natural products to elaborate contract research for clients in these industries. The Company provides a range of consulting services in the areas of regulatory support, new ingredient or product development, risk management and litigation support. With an addition of Spherix, it provides regulatory approval and scientific advisory services.

The Company competes with Sigma-Aldrich, Phytolab, US Pharmacopoeia, Extrasynthese, Covance, Eurofins, and Silliker Canada Co.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap stocks Chromadex Corp (OTCMKTS: CDXC) and 22nd Century Group Inc (OTCBB: XXII) are, one way or the other, focused on natural products and have been getting some extra attention lately. Moreover, one of these stocks have been the subject of a disclosed investor awareness campaign. Keeping that in mind, are these two small cap stocks natural winners for investors? Here is a quick look:

Top Biotech Companies To Invest In 2015: Biodel Inc (BIOD)

Biodel Inc. (Biodel), incorporated on December 3, 2003, is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).

The Company has two pivotal Phase III clinical trials with its preferred commercial formulation of Linjeta prior to re-submitting the NDA. In August 2011, it completed patient visits and analyzed top-line data from the first Phase 1 clinical trial of two RHI-based formulations. The trial was a single-center, randomized, double-blind, three-period crossover trial in 18 subjects with Type 1 diabetes. The purpose of the trial was to evaluate the pharmacokinetic and pharmacodynamic characteristics and injection site toleration of BIOD-105 and BIOD-107, as compared to the insulin analog marketed as Humalog. The Company conducted Phase I, Phase II and Phase III clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin, which is a branded formulation of RHI or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.

The Company competes with Eli Lilly, Novo Nordisk, Sanofi-Aventis, Halozyme Therapeutics, Inc. and MannKind Corporation.

Advisors' Opinion:
  • [By Monica Gerson]

    Biodel (NASDAQ: BIOD) is expected to post a Q1 loss at $0.24 per share.

    First Majestic Silver (NYSE: AG) is estimated to post its Q1 earnings at $0.10 per share on revenue of $63.35 million.

  • [By Roberto Pedone]

    One under-$10 specialty biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Biodel (BIOD), which is focused on the development and commercialization of innovative treatments for diabetes. This stock has been hit hard by the bears over the last three months, with shares down by 24%.

    If you take a look at the chart for Biodel, you'll notice that this stock is ripping higher here right off its 50-day moving average of $2.32 a share with strong upside volume. Volume on Thursday has so far registered over 750,000 shares, which is well above its three-month average action of 445,084 shares. This move is quickly pushing shares of BIOD within range of triggering a big breakout trade.

    Traders should now look for long-biased trades in BIOD if it manages to break out above some near-term overhead resistance levels at $2.52 to $2.60 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 445,084 shares. If that breakout triggers soon, then BIOD will set up to re-test or possibly take out its next major overhead resistance levels $3 to its 200-day moving average of $3.39 a share. Any high-volume move above $3.39 will then give BIOD a chance to tag $4 a share.

    Traders can look to buy BIOD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $2.10 a share. One can also buy BIOD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Biotech Companies To Invest In 2015: Nektar Therapeutics(NKTR)

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The company?s product pipeline consists of drug candidates across various therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. Its research and development activities involve small molecule drugs, peptides, and other potential biologic drug candidates. The company?s proprietary drug candidates in clinical development comprise NKTR-118, a peripheral opioid antagonist, which has completed Phase II clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase II clinical trail to treat gram-negative pneumonias; NKTR-102, a topoisomerase I inhibitor-polymer conjugate, which is in Phase II clinical trail for multiple cancer indications, including breast, ovarian, and colorectal; and NKTR-105 that is in Phase I clinica l trail to treat solid tumors. Its preclinical products consists of NKTR-119 (Opioid/NKTR-118 combinations) for the treatment of pain; NKTR-181 (abuse deterrent, tamper-resistant opioid) to treat pain; NKTR-194 (non-scheduled opioid) for the treatment of mild to moderate pain; NKTR-171 (tricyclic antidepressant) to treat neuropathic pain; and NKTR-140 (protease inhibitor candidate) to treat HIV. The company has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. In addition, Nektar Therapeutics has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, Baxter, Roche, Merck, Pfizer, and UCB Pharma. The company was founded in 1990 and is headquartered in San Franc isco, California.

Advisors' Opinion:
  • [By Jay Silverman]

    Jay Silverman: Oh, by the way, if you wanted me to throw a few of those names that might be considered, Novavax would be one of them, and Nektar (NKTR), and the Medicines Company (MDCO) and Pharmacyclics, which has been a great stock, but has come under pressure of late.

  • [By Sean Williams]

    Nektar Therapeutics (NASDAQ: NKTR  ) delivered a double-digit gain for shareholders this week after reporting positive top-line data for NKTR-181, its oral chronic pain-treatment drug. NKTR-181 is an opioid-based compound that's designed to enter the brain slower than traditional opiates like oxycodone without sacrificing effectiveness and ultimately reducing addiction-like qualities to the medication. In trials, the data demonstrated that NKTR-181 had a statistically significant lower "drug liking" and "feeling high" score than oxycodone. While I'd certainly exercise caution in getting too excited, as the Food and Drug Administration is very harsh with regard to its regulation of opioid-based drugs, it's nonetheless good news for Nektar.

  • [By Lu Wang]

    Nektar Therapeutics (NKTR) tumbled 24 percent, its biggest slide in five years, to $10.54. The company said a study of the slow-release painkiller NKTR-181 showed it failed to meet the primary endpoint of a Phase 2 study, citing an ��nusual lack��of a gain in pain scores for patients taking a placebo.

  • [By Rich Bieglmeier]

    Wednesday, June 11, 2014 could be a happy or sad day for event traders who follow the Food and Drug Association's (FDA) calendar. Two biotechs with considerable potential are slated to hear from the regulatory body regarding their applications for approval.

    Nektar Therapeutics (NASDAQ:NKTR) Orexigen Therapeutics, Inc. (NASDAQ:OREX)

    The duo hopes to see �thumbs up from the FDA in a little more than a week. If all things go well, it could be party time for shareholders too.

Top Biotech Companies To Invest In 2015: ViroPharma Incorporated(VPHM)

ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. It focuses on developing products used by physician specialists or in hospital settings. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by staphylococcus aureus, including methicillin-resistant strains. It also offers Plenadren, an orphan drug for treatment of adrenal insufficiency in adults; Buccolam, a oromucosal solution for treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children, and adolescents; and maribavir, an antiviral compound for the treatment o f CMV disease through a license agreement with GlaxoSmithKline. The company?s primary development programs include Cinryze, a C1 esterase inhibitor for management of hereditary angioedema; and VP 20621, a non-toxigenic strain of C. difficile. Its clinical stage drug candidate comprises VP-20629 for the treatment of Friedreich?s Ataxia. The company sells its products directly to wholesale drug distributors and specialty pharmacies/distributors. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania.

Advisors' Opinion:
  • [By John Udovich]

    Small cap orphan drug stocks Zalicus Inc (NASDAQ: ZLCS), Omeros Corporation (NASDAQ: OMER) and Viropharma Inc (NASDAQ: VPHM) have been active lately thanks to good news about their orphan drug treatments. In case you aren�� familiar with the term, orphan drug designation by the FDA is granted for drugs targeting conditions affecting 200,000 or fewer US patients annually that are expected to provide significant therapeutic advantage over existing treatments. The designation will also qualify companies for benefits across all stages of drug development, such as�accelerated approval processes, seven years of market exclusivity�after marketing approval, tax credits on�any US�clinical trials, grants and waiver of certain administrative fees.

  • [By Paul Ausick]

    Stocks on the Move: ViroPharma Inc. (NASDAQ: VPHM) is up 25.4% at $49.38 on a $4.2 billion buyout offer from London-listed Shire. Zalicus Inc. (NASDAQ: ZLCS) is down 72.3% at $1.30 on a failed drug trial.

  • [By MONEYMORNING]

    On Monday, Dublin-based pharmaceutical firm Shire (Nasdaq ADR: SHPG) announced that it will buy Pennsylvania-based ViroPharma (Nasdaq: VPHM) for $4.2 billion in cash. The $50 per share purchase price is a 27% premium to Viropharma's Friday close and a 64% premium to the price when sale rumors first emerged this summer.